002020 京新药业
已收盘 03-03 15:00:00
资讯
新帖
简况
股市必读：京新药业（002020）2月27日董秘有最新回复
证券之星 · 03-02 03:11
股市必读：京新药业（002020）2月27日董秘有最新回复
京新药业：降脂新药LP（a）JX2201的临床I期已完成入组
证券之星 · 02-28
京新药业：降脂新药LP（a）JX2201的临床I期已完成入组
京新药业：公司在努力推进地达西尼的销售工作
证券之星 · 02-28
京新药业：公司在努力推进地达西尼的销售工作
京新药业：盐酸卡利拉嗪胶囊正在推进其审评工作
证券之星 · 02-26
京新药业：盐酸卡利拉嗪胶囊正在推进其审评工作
京新药业：人工大血管项目正在有序推进验证性临床
证券之星 · 02-26
京新药业：人工大血管项目正在有序推进验证性临床
京新药业（002020）披露更换持续督导保荐代表人公告，2月24日股价上涨0.24%
证券之星 · 02-24
京新药业（002020）披露更换持续督导保荐代表人公告，2月24日股价上涨0.24%
京新药业公布国际专利申请：“药物组合物”
证券之星 · 02-14
京新药业公布国际专利申请：“药物组合物”
思源电气、京新药业、博纳西亚、和夏科技递表港交所；京东科技发布“京东AI付”丨港交所早参
每日经济新闻 · 02-13
思源电气、京新药业、博纳西亚、和夏科技递表港交所；京东科技发布“京东AI付”丨港交所早参
京新药业：向香港联交所递交H股发行上市申请
每日经济新闻 · 02-12
京新药业：向香港联交所递交H股发行上市申请
新股消息 | 京新药业(002020.SZ)递表港交所
智通财经 · 02-12
新股消息 | 京新药业(002020.SZ)递表港交所
京新药业：盐酸卡利拉嗪若后续顺利获批，商业化策略会根据产品本身的特点，并借鉴地达西尼的销售经验来推进
证券之星 · 02-08
京新药业：盐酸卡利拉嗪若后续顺利获批，商业化策略会根据产品本身的特点，并借鉴地达西尼的销售经验来推进
京新药业：公司的重酒石酸卡巴拉汀目前销售额较小
证券之星 · 01-30
京新药业：公司的重酒石酸卡巴拉汀目前销售额较小
京新药业：现有销售团队对于精神神经领域的药品销售有一定的经验
证券之星 · 01-30
京新药业：现有销售团队对于精神神经领域的药品销售有一定的经验
京新药业：公司启动H股上市计划主要为与公司创新转型战略相匹配
证券之星 · 01-30
京新药业：公司启动H股上市计划主要为与公司创新转型战略相匹配
京新药业（002020）披露2026年第一次临时股东会决议公告，1月28日股价下跌2.92%
证券之星 · 01-28
京新药业（002020）披露2026年第一次临时股东会决议公告，1月28日股价下跌2.92%
股市必读：京新药业（002020）1月23日董秘有最新回复
证券之星 · 01-26
股市必读：京新药业（002020）1月23日董秘有最新回复
京新药业：公司LP（a）的对外授权和盐酸卡利拉嗪都在正常推进中
证券之星 · 01-25
京新药业：公司LP（a）的对外授权和盐酸卡利拉嗪都在正常推进中
京新药业（002020）披露第四期员工持股计划首次授予部分非交易过户完成，1月22日股价下跌1.74%
证券之星 · 01-22
京新药业（002020）披露第四期员工持股计划首次授予部分非交易过户完成，1月22日股价下跌1.74%
京新药业：AI在研发的应用还处在持续摸索阶段
证券之星 · 01-16
京新药业：AI在研发的应用还处在持续摸索阶段
京新药业(002020.SZ)筹划赴港上市事项
智通财经 · 01-13
京新药业(002020.SZ)筹划赴港上市事项
加载更多
公司概况
公司名称：
浙江京新药业股份有限公司
所属行业：
医药制造业
上市日期：
2004-07-15
主营业务：
浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、传统中药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。
发行价格：
10.05
{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":15.57,"timestamp":1772521410000,"preClose":15.89,"halted":0,"volume":11209728,"delay":0,"changeRate":-0.0201,"floatShares":724000000,"shares":861000000,"eps":0.8276,"marketStatus":"已收盘","change":-0.32,"latestTime":"03-03 15:00:00","open":15.89,"high":16.13,"low":15.5,"amount":177000000,"amplitude":0.0396,"askPrice":15.57,"askSize":161,"bidPrice":15.54,"bidSize":40,"shortable":0,"etf":0,"ttmEps":0.8276,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772587800000},"marketStatusCode":5,"adr":0,"adjPreClose":15.89,"symbolType":"stock","openAndCloseTimeList":[[1772501400000,1772508600000],[1772514000000,1772521200000]],"highLimit":17.48,"lowLimit":14.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"isCdr":false,"pbRate":2.42,"roa":"--","peRate":18.813436,"roe":"10.1%","epsLYR":0.83,"committee":0.077577,"marketValue":13406000000,"turnoverRate":0.0155,"status":1,"floatMarketCap":11272000000},"requestUrl":"/m/hq/s/002020","defaultTab":"news","newsList":[{"id":"2616876100","title":"股市必读：京新药业（002020）2月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2616876100","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616876100?lang=zh_cn&edition=full","pubTime":"2026-03-02 03:11","pubTimestamp":1772392269,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，京新药业报收于16.34元，上涨0.62%，换手率0.98%，成交量7.13万手，成交额1.17亿元。董秘最新回复投资者： 问公司吕董，公司地达西尼26年前两月环比去年四季度销售额增长了吗？公司在努力推进地达西尼的销售工作，目前销售情况良好。公司的降脂新药LPJX2201的临床I期已完成入组，正在完善临床报告。当日关注点来自交易信息汇总：2月27日主力资金净流出314.61万元，游资资金净流出465.8万元，散户资金净流入780.41万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2614981363","title":"京新药业：降脂新药LP（a）JX2201的临床I期已完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2614981363","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614981363?lang=zh_cn&edition=full","pubTime":"2026-02-28 16:21","pubTimestamp":1772266869,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)02月28日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司降脂新药，一期临床结束了吗？效果如何？BD推进到什么程度了。怏一年了！！！京新药业回复：您好！公司的降脂新药LP（a）JX2201的临床I期已完成入组，正在完善临床报告。对外授权工作也在推进中。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022800009442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2614813932","title":"京新药业：公司在努力推进地达西尼的销售工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2614813932","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614813932?lang=zh_cn&edition=full","pubTime":"2026-02-28 16:21","pubTimestamp":1772266866,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)02月28日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司地达西尼26年前两月环比去年四季度销售额增长了吗？京新药业回复：您好!公司在努力推进地达西尼的销售工作，目前销售情况良好。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022800009439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2614018259","title":"京新药业：盐酸卡利拉嗪胶囊正在推进其审评工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2614018259","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614018259?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:21","pubTimestamp":1772094092,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：盐酸卡利拉嗪胶囊评审公示已经撤除，是不是评审阶段已经结束，等待批文？京新药业回复：您好！盐酸卡利拉嗪胶囊正在推进其审评工作，暂未收到批准上市的批文。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600023557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2614001827","title":"京新药业：人工大血管项目正在有序推进验证性临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2614001827","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614001827?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:18","pubTimestamp":1772093892,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董公司人工大西管一期临床结束了吗？效果如何？还是二期呢？京新药业回复：您好！人工大血管项目正在有序推进验证性临床。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600023485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2613188497","title":"京新药业（002020）披露更换持续督导保荐代表人公告，2月24日股价上涨0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613188497","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613188497?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:10","pubTimestamp":1771931454,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，京新药业报收于16.65元，较前一交易日上涨0.24%，最新总市值为143.36亿元。京新药业于2026年2月24日披露《关于更换持续督导保荐代表人的公告》。变更后，持续督导保荐代表人为朱翔坚、龙佳喜，持续督导责任至募集资金使用完毕为止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400038447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2611195934","title":"京新药业公布国际专利申请：“药物组合物”","url":"https://stock-news.laohu8.com/highlight/detail?id=2611195934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611195934?lang=zh_cn&edition=full","pubTime":"2026-02-14 05:44","pubTimestamp":1771019090,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示京新药业（002020）公布了一项国际专利申请，专利名为“药物组合物”，专利申请号为PCT/CN2025/112343，国际公布日为2026年2月12日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来京新药业已公布的国际专利申请1个，与去年同期持平。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了1.85亿元，同比减6.15%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021400002706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2611697917","title":"思源电气、京新药业、博纳西亚、和夏科技递表港交所；京东科技发布“京东AI付”丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2611697917","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611697917?lang=zh_cn&edition=full","pubTime":"2026-02-13 01:54","pubTimestamp":1770918850,"startTime":"0","endTime":"0","summary":"NO.1思源电气、京新药业、博纳西亚递表港交所主板据港交所2月11日消息，思源电气股份有限公司（以下简称思源电气，SZ002028）、浙江京新药业股份有限公司（以下简称京新药业，SZ002020）、博纳西亚（杭州）医药科技股份有限公司（以下简称博纳西亚）已向港交所主板递交上市申请。据其各自招股书，思源电气是全球输配电设备制造商及电力能源综合解决方案提供商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602133649599961.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602133649599961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09618","LU0499858602.USD","LU0868486357.SGD","LU1282651121.HKD","BK1615","IE0032431581.USD","LU0211977185.USD","LU0463099449.HKD","LU0315178854.USD","LU0370786039.SGD","LU1303224171.USD","LU0345775950.USD","LU1282649810.SGD","LU0320764599.SGD","BK1591","IE0008368742.USD","BK4524","BK1142","LU0572944931.SGD","LU2289578879.USD","LU0499858438.USD","IE00BGV7N243.SGD","LU1224444064.USD","LU0039217434.USD","LU0228367735.SGD","LU0828237510.HKD","LU0348825331.USD","LU1044875133.USD","LU0164865239.USD","LU0348805143.USD","002020","LU1023057109.AUD","BK0239","LU1813983027.USD","LU2242644610.SGD","BK4588","LU0469268626.HKD","IE00B3M56506.USD","LU0417516902.SGD","BK0078","LU1820825898.SGD","LU1655091616.SGD","LU0348735423.USD","00751","BK4558","LU1366334578.USD","LU1642822792.SGD","LU1997244956.HKD","JD","LU1770036033.HKD","89618","LU0431992006.USD","LU0588545490.SGD","LU1688375341.USD","SG9999002562.SGD","LU0672654166.SGD","LU1366334651.USD","BK4551","LU0417516738.SGD","BK4503","BK4526","LU0293314216.USD","LU1044876610.USD","LU2476274720.SGD","LU0588545904.SGD","BK0069","LU2213484517.USD","BK0188","LU1328277881.USD","LU1997245177.USD","LU1188198961.HKD","LU0359201885.HKD","LU2065171311.SGD","SWDHY","BK4122","LU0084288322.USD","BK4614","BK4505","LU0307460666.USD","LU0326950275.SGD","LU1251922891.USD","IE00B29SXG58.USD","IE00B5MMRT66.SGD","LU2328871848.SGD","BK0156","LU1282651048.USD","LU2778985437.USD","002028","SG9999011746.SGD","IE00BYTNYN87.SGD","LU0320764755.SGD","LU1969619763.USD","LU0456846285.SGD","LU1282649067.USD","LU0048580855.USD","BK0224","LU2460026573.USD","LU0543330483.HKD","LU1794554557.SGD","BK1502","LU0359202008.SGD","SG9999002828.SGD","LU2399975544.HKD","LU0327786744.USD","BK1588","LU2065170008.USD","LU2039709279.SGD","LU0228659784.USD","LU0708995583.HKD","LU0163747925.USD","BK4579","LU0588546209.SGD","BK1575","LU1880383366.USD","LU0345776255.USD","LU0650527681.SGD","LU1720050803.USD","HK0000306685.HKD","HK0000320223.HKD","HK0000306701.USD","LU1719994722.HKD","LU0791591158.USD","LU0244354667.USD","LU0052750758.USD","LU1961090484.USD","LU0791590937.USD","BK4509","LU0456842615.SGD","LU1770034418.SGD","LU0140636845.USD","BK1610","LU0315179316.USD","BK4504","HK0000320264.USD","LU0164880469.USD","LU1146622755.USD","BK4220","LU0259732245.USD","LU0231483743.USD","LU1044874839.SGD","BK4531","LU2476274308.USD","LU1808992512.USD","LU1481107354.HKD","LU2065169927.USD","LU0359201612.USD","IE00BYQNZ168.SGD","LU0531971595.HKD","LU0128522157.USD","IE00B543WZ88.USD","SG9999001226.SGD","LU0594300419.USD","BK1619","LU0488056044.USD","LU2065171402.SGD","LU0871576103.HKD","LU0384037296.USD","BK0028","LU0588545730.USD","IE00B12V2V27.USD","IE00BPRC5H50.USD","BK4585","LU0865486749.SGD","LU0456827905.SGD","LU0051755006.USD","LU0314109678.HKD","LU1997245094.SGD","SG9999002463.SGD","LU1255011170.USD","LU0029875118.USD","BK1249","LU2257852520.SGD","LU0149721374.USD","LU2495084118.USD","LU0106959298.USD"],"gpt_icon":1},{"id":"2610610998","title":"京新药业：向香港联交所递交H股发行上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2610610998","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610610998?lang=zh_cn&edition=full","pubTime":"2026-02-12 08:13","pubTimestamp":1770855180,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月12日，京新药业公告称，公司已于2026年2月11日向香港联交所递交了发行境外上市股份（H股）并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行并上 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260212/c674748205.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260212/c674748205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2610962002","title":"新股消息 | 京新药业(002020.SZ)递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2610962002","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610962002?lang=zh_cn&edition=full","pubTime":"2026-02-12 06:35","pubTimestamp":1770849320,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所2月11日披露，浙江京新药业股份有限公司(简称：京新药业)向港交所主板递交上市申请，中信证券为其独家保荐人。招股书显示，京新药业(002020.SZ)是一家以创新为驱动力的制药集团，策略重点专注于两大核心疾病领域：中枢神经系统疾病；及心血管及脑血管疾病。公司的商业模式将已上市产品的商业化与产品管线的持续推进相结合。当前产品组合涵盖药物(包括仿制药、创新药物、中药及生物制剂)；原料药；及医疗设备。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002020","BK0239","HEXmain"],"gpt_icon":0},{"id":"2609471520","title":"京新药业：盐酸卡利拉嗪若后续顺利获批，商业化策略会根据产品本身的特点，并借鉴地达西尼的销售经验来推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2609471520","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609471520?lang=zh_cn&edition=full","pubTime":"2026-02-08 13:36","pubTimestamp":1770528970,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)02月08日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司盐酸卡利拉嗪不出意外可以说十天内就出批文了！做为令球大单品。估计国内峰值30亿以上，公司做好生产销售准备了吗？京新药业回复：您好！盐酸卡利拉嗪胶囊若后续顺利获批，商业化策略会根据产品本身的特点，并借鉴地达西尼的销售经验来推进。公司会做好盐酸卡利拉嗪的商业化工作，争取取得好的销售业绩。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800002752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2607804591","title":"京新药业：公司的重酒石酸卡巴拉汀目前销售额较小","url":"https://stock-news.laohu8.com/highlight/detail?id=2607804591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607804591?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:24","pubTimestamp":1769779452,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)01月30日在投资者关系平台上答复投资者关心的问题。投资者提问：印度产的重酒石酸卡巴拉汀胶囊被禁对公司而言是个好机会，目前公司国内份额多少？一年销售额多少？未来公司抓住机会可以扩大份额有信心吗？京新药业回复：您好!公司的重酒石酸卡巴拉汀目前销售额较小，公司希望后续可以通过集采机会获得好的销售业绩。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000045264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2607459450","title":"京新药业：现有销售团队对于精神神经领域的药品销售有一定的经验","url":"https://stock-news.laohu8.com/highlight/detail?id=2607459450","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607459450?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:24","pubTimestamp":1769779452,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)01月30日在投资者关系平台上答复投资者关心的问题。投资者提问：公司申请上市的盐酸卡利拉嗪胶囊上市评审结束了，最快什么时候可以销售？公司做好生产上市准备了吗？预计国内市场规模大约多少？京新药业回复：您好！公司现有销售团队对于精神神经领域的药品销售有一定的经验，预期可以有效承接盐酸卡利拉嗪的商业化工作，争取取得好的销售业绩。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000045261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2607045912","title":"京新药业：公司启动H股上市计划主要为与公司创新转型战略相匹配","url":"https://stock-news.laohu8.com/highlight/detail?id=2607045912","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607045912?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:24","pubTimestamp":1769779444,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)01月30日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，A股上市企业去港股再上市，规定市值超400亿港币，或近一年利润不低于10亿港币，公司申请港股上市，目前符合那条，应该说利润9亿人民币更好达到吧！京新药业回复：您好！公司会按照监管规则推进H股上市事项，公司启动H股上市计划主要为与公司创新转型战略相匹配，坚持研发投入，做好创新布局，建立公司第二增长曲线。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000045258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2606712224","title":"京新药业（002020）披露2026年第一次临时股东会决议公告，1月28日股价下跌2.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712224","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606712224?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:09","pubTimestamp":1769609359,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，京新药业报收于16.94元，较前一交易日下跌2.92%，最新总市值为145.86亿元。该股当日开盘17.46元，最高17.49元，最低16.83元，成交额达4.23亿元，换手率为3.43%。近日，京新药业发布《2026年第一次临时股东会决议公告》。表决结果均达到法定通过比例，会议召集程序合法合规。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2606539265","title":"股市必读：京新药业（002020）1月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606539265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606539265?lang=zh_cn&edition=full","pubTime":"2026-01-26 03:05","pubTimestamp":1769367912,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，京新药业报收于18.05元，上涨0.11%，换手率1.44%，成交量10.42万手，成交额1.88亿元。公司公告汇总第四期员工持股计划首次授予部分非交易过户完成公告浙江京新药业股份有限公司已完成第四期员工持股计划首次授予部分的非交易过户。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":1},{"id":"2606525088","title":"京新药业：公司LP（a）的对外授权和盐酸卡利拉嗪都在正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2606525088","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606525088?lang=zh_cn&edition=full","pubTime":"2026-01-25 22:12","pubTimestamp":1769350337,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)01月25日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，大盘近几个月如此给力，公司却如此狼狈，而且公司回复问题还遮遮掩掩，毫无正能量，公司的BD业务以及盐酸卡利拉嗪进度什么情况？一切正常吗？为什么公司从不正面回复京新药业回复：您好！谢谢您对公司的关注，公司LP（a）的对外授权和盐酸卡利拉嗪都在正常推进中。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500009303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2605922144","title":"京新药业（002020）披露第四期员工持股计划首次授予部分非交易过户完成，1月22日股价下跌1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605922144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605922144?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:15","pubTimestamp":1769091320,"startTime":"0","endTime":"0","summary":"近日，浙江京新药业股份有限公司披露第四期员工持股计划首次授予部分非交易过户完成公告。公司已完成第四期员工持股计划首次授予部分的非交易过户，公司回购专用账户中的712.34万股A股股票已于2026年1月21日通过非交易过户方式过户至员工持股计划专用账户，占公司总股本的0.83%，过户价格为12.50元/股。员工持股计划存续期为60个月，股票分三期解锁，解锁比例分别为40%、30%、30%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200040630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2603995447","title":"京新药业：AI在研发的应用还处在持续摸索阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2603995447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603995447?lang=zh_cn&edition=full","pubTime":"2026-01-16 20:52","pubTimestamp":1768567922,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)01月15日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在AI制药方面有应用？京新药业回复：您好！公司目前AI在研发的应用，还处在持续摸索阶段。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600038751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2603521415","title":"京新药业(002020.SZ)筹划赴港上市事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2603521415","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603521415?lang=zh_cn&edition=full","pubTime":"2026-01-13 06:31","pubTimestamp":1768257104,"startTime":"0","endTime":"0","summary":"智通财经APP讯，京新药业(002020.SZ)公告，公司拟发行境外上市股份(H股)并申请在中国香港联交所主板挂牌上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002020","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772527314571,"stockEarnings":[{"period":"1week","weight":-0.0433},{"period":"1month","weight":-0.0636},{"period":"3month","weight":-0.1855},{"period":"6month","weight":-0.223},{"period":"1year","weight":0.2654},{"period":"ytd","weight":-0.1628}],"compareEarnings":[{"period":"1week","weight":0.0246},{"period":"1month","weight":0.0157},{"period":"3month","weight":0.0731},{"period":"6month","weight":0.0968},{"period":"1year","weight":0.2595},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"22318人(较上一季度减少86.05%)","perCapita":"0股","listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","registeredCapital":"86102万元","survey":" 浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、传统中药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","listedPrice":10.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}